2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2658

Cognitive Symptoms and Associated Disease and Non-Disease Related Factors in Patients with Systemic Lupus Erythematosus : A Longitudinal Study
Abstract Number: 1112

Cognitive Symptoms in Fibromyalgia Patients Compared with Rheumatoid Arthritis Patients
Abstract Number: 247

Cognitive Task Related Hypoperfusion of Frontal Gyrus in Patients with Chronic Fatigue
Abstract Number: 156

Colchicine and the Risk of Acute Cardiovascular (CV) Events Among Gout Patients: The New York Department of Veterans Affairs Retrospective Cohort Study
Abstract Number: 1356

Collaboration Between a Third Party Payer and Community Rheumatologists to Create a Clinical Pathway for the Treatment of Rheumatoid Arthritis to Assure Proper Use of Biologics and Quality of Care
Abstract Number: 541

Collagen II Neo-Epitopes in Spondyloarthritis.
Abstract Number: 794

Color Doppler Ultrasonography Findings in Giant Cell Arteritis and Their Relationship with Clinical Manifestations
Abstract Number: 123

Combination with Joint Power Doppler Signals with Anti-Citrullinated Peptide Antibody Predicts Joint Destruction in Rheumatoid Arthritis
Abstract Number: 2231

Combined Chondroitin Sulfate and Glucosamine Is Comparable to Celecoxib for Painful Knee Osteoarthritis. Results from a Multicenter, Randomized, Double-Blind, PHASE IV NON-Inferiority TRIAL
Abstract Number: 601

Combined Hip Abduction Angle Measured By Using Iphone Compass Application; A Novel Measurement Tool to Asses Hip Mobility
Abstract Number: 638

Commensal Microbiota Influence Systemic Autoimmune Responses
Abstract Number: 2114

Comorbidity Characteristics of Patients Starting First-Line Acute Gout Agents – Colchicine, NSAID, and Corticosteroids
Abstract Number: 1406

Comorbidity in Rheumatoid Arthritis. It Is Feasible to Record Concomitant Medical Conditions and Multi-Morbidity in Observational Research Studies. Can This be Extended to Routine Clinical Settings?
Abstract Number: 1313

Comorbidity Patterns in Children with Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus: The Childhood Arthritis and Rheumatology Research Alliance Registry
Abstract Number: 2823

Comparable Efficacy with Sarilumab Plus Methotrexate in Biologic-Experienced and Biologic-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis from a Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].